A Case of Non-alcoholic Steatohepatitis Treated with Herbal Medicine

Chang-Gue Son
Liver and Immunology Research Center, Oriental Medical College in Daejeon University

Objective: To understand the characteristic of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and study the traditional Korean medicine (TKM)-based strategies or therapeutics for them.

Methods: A male patient with NASH was treated with only Oriental therapies, and then the clinical outcome was evaluated by serum biochemical parameters and radiographs.

Result: The clinical and biochemical values of the patient fluctuated over three years according to the treatments and cessation of herbal medicines.

Conclusion: NASH or NAFLD are now prevalent and these disorders could be targets of TKM, and this case report would provide useful information.

Key Words: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, traditional Korean medicine, herbal medicine

Introduction

Non-alcoholic fatty liver disease (NAFLD) refers to hepatic disorders which are characterized as fatty liver changes not due to excessive alcohol use\(^1\). This disorder was once rare, but has currently reached epidemic proportions in developed countries\(^2\). NAFLD covers a wide range of disease status, from only fatty accumulation to progressive hepatic inflammation in the liver. In general, most patients with NAFLD have few or no symptoms, and a liver can remain fatty without disturbing liver function. However, some patients infrequently progress to outright hepatic inflammation, so called non-alcoholic steatohepatitis (NASH)\(^3\).

Over time, NASH may progresses into fibrosis, cirrhosis (20%), liver failure (9%) or hepatocellular carcinoma (1%), so it is regarded as a major cause of cirrhosis of the liver of unknown cause\(^4,5\). According to the change of lifestyle leading to over-nutrition, insulin resistance and a highly disordered metabolic milieu, the prevalence of NASH has been increasing\(^6\). The etiology of NASH is still unclear and the development of therapeutics is extremely urgent\(^7,8\).

Traditional Korean medicine (TKM) has treated patients with various hepatic diseases for thousands years, and many herbal plants or formulae are being investigated as hepatotherapeutics\(^9,10\). However, the clinical experiences and academic reports on NAFLD or NASH in TKM field are very few. This case report presents a patient with NASH in order to...
provide a clinical characteristic and the possibility of herbal therapeutics.

**Report of the case**

1. Characteristics of patient and diagnosis

A 33-year-old man visited hepatology department complaining about his chronic fatigue symptoms. He had already recognized his abnormal liver function test from previous medical examination in western hospital. Laboratory data showed elevated serum activity of alanine and aspartate aminotransferase (ALT and AST), gamma-glutamyl transferase (GGT), as 155 IU/L, 118 IU/L, and 278 IU/L respectively. Tests for viral infection and auto-immune hepatitis were negative (HAV-Ig G: positive, HBs Ab: positive, HCV Ab: negative, antinuclear Ab: negative and smooth muscle Ab: negative respectively). The patient has been a smoker but not used alcohol usually. He usually underwent high level of physical activity and psychological stress due to his own business of an indoor driving range. Abdominal ultrasonography and computed topography revealed no abnormal features except moderate fatty liver (Fig. 1). He was slightly obese by 27 body mass index (BMI) without hyperlipidemia (about 124 mg/dl of total cholesterol and 122 mg/dl of triglyceride), and has a positive family history for hepatoma in his father.

2. Herbal drugs and treatments

The patient has been treated both as an outpatient and inpatient. CGX syrup (three packs per day) and other herbal prescriptions such as *Injinohryungsan* were given to the patient. CGX syrup was composed of 13 herb extracts; 5 g each of Artemisia capillaris Herba, Carapax Trionycis, Semen Raphani; 3 g each of Rhizoma Atractylodis Macrocephalae, Poria, Alismatis Rhizoma, Atractylodis Rhizoma, Salviae Miltiorrhizae Radix; 2 g each of Polyborus, Amomi Fructus, Aurantii Fructus, and 1 g of Glycyrrhizae Radix and Helenii Radix. Acupuncture (mainly at HT4, LU9, LR3), moxibustion (CV4, CV8) and pharmacopuncture (CV4 with Yidam) were practiced irregularly. The patient has been recommended to reduce meat intake and exercise regularly.

3. Course of symptoms and lab examination

The patient has been irregularly treated for three years at Daejeon Oriental hospital. He didn’t complain of any liver-related symptoms including bleeding tendency, jaundices, edema, or abdomen discomfort while undergoing frequent general fatigue, eye fatigue and sputum in the airway. The patient visited an Oriental hospital whenever he felt severe fatigue. General liver function tests and ultrasonography were performed around every six months, and computed topography yearly. The patient felt a good physical feeling, decrease of fatigue severity along with treatments, while serum levels of AST, ALT and GGT fluctuated between normal and about three-folds of physiological range (Table 1). Other hematological parameters including platelet count, prothrombin time, albumin, alpha fetoprotein (AFP)
Tested day | AST (IU/L) | ALT (IU/L) | GGT (IU/L) | ALP (IU/L) | T. bilirubin (mg/dl) | Radiology (Sono or CT)
--- | --- | --- | --- | --- | --- | ---
Feb. 22, 2008 | 155 | 118 | 278 | 384 | 2.9 | Fatty liver grade 2-3
Aug. 25, 2008 | 28 | 61 | 25 | 61 | 0.6 | -
Oct. 27, 2008 | 41 | 114 | 37 | 76 | 0.6 | Fatty liver grade 2
Jun 08, 2009 | 23 | 42 | 22 | 80 | 0.6 | Fatty liver grade 2
Oct. 04, 2010 | 85 | 171 | 4 | 77 | 2.1 | -
Dec. 23, 2010 | 30 | 90 | 35 | 83 | 0.9 | Fatty liver grade 2
Feb. 21, 2011 | 34 | 81 | 30 | 73 | 0.9 | Fatty liver grade 2

The diagnosis of fatty liver is described as grade 0 to 3 based on the increased echogenicity, liver-kidney contrast, vascular blurring and deep attenuation. No abnormal finding in computed topography except fatty liver.

Discussion and Conclusion

NASH is the most extreme form of NAFLD, which causes inflammation and accumulation of fat and fibrous tissue in the liver. Patients with NASH are most often discovered during routine laboratory tests because of presence of no NASH-specific symptoms except general fatigue. The patient of this report complained only of fatigue including eye fatigue and respiratory sputum. NASH has been known to not develop serious liver problems; however some patients progress to liver fibrosis or cirrhosis. Via over-time observation of NASH patients, one study reported that the condition of NASH improved in about 3%, remained stable in 54%, and worsened in 43% of people into fibrosis or cirrhosis.

This patient was not diagnosed with NASH before visiting the Oriental hospital, but recognized just as abnormal liver function in western hospitals. Biochemical and imaging tests reveal hepatic damage and fat accumulation in the liver, but cannot differentiate NASH from other causes of liver disease. Although liver biopsy is required to confirm NASH, it is invasive and has drawbacks in sampling and interpretation error. This patient could be diagnosed into NASH based on biochemical results and imaging finding as well as exclusive factors (viral infection, immunological test and none history of alcohol use) without liver biopsy.

Due to his concern about the risk of progress to worse disorders, he stopped cigarette smoking and made an effort at weight control and more vegetarian diet. NASH is strongly associated with metabolic syndrome (diabetes, obesity, combined hyperlipidemia, and hypertension) and insulin resistance, and smoking is associated with histological severity. However, the exact cause of NASH and underlying mechanisms of progress into inflammation from hepatic steatosis are unknown. Oxidative stress is considered as a potential cause of further injury in NASH progress. Genetic polymorphisms and genetic mutations for high prevalence of NASH or NAFLD were identified, and are associated with the susceptibility against hyperlipidemia, insulin resistance and oxidative stress. The patient had no insulin resistance but hyperlipidemia, and family history of father’s hepatoma. The father wasn’t an HBV carrier but used to drink alcohol, so the cause of the hepatoma cannot be accurately proposed.
A Case of Non-alcoholic Steatohepatitis Treated with Herbal Medicine

The physical symptoms and laboratory findings generally improved along with treatment; however, they frequently fluctuated if the treatment was stopped. The main treatments in Oriental hospital were herbal prescriptions (CGX and others), acupuncture, moxibustion (CV4 and CV8) and pharmacopuncture (CV4 with Yidam). To date, there is no standardized therapy for NASH in western medicine, and lifestyle modifications for metabolic syndrome such as change of diet, weight loss and control of lipid levels are strongly suggested. Some herbal plants and prescriptions with antioxidant properties have shown positive results in NASH. CGX prescribed to the patient has also been evidenced to possess potential antioxidant actions. This patient responded positively to herbal medicine and other treatments in Oriental hospital. For three years, no pathologically progressive signs were observed in consecutive examination of blood tests and radiological findings. However, these therapeutics were not completely curative owing to relapse of the disorder. In fact, NASH is a chronic disease, thus the patient should be treated continuously. This patient showed typical features of NASH.

NAFLD and NASH patients are increasing in number in developed countries worldwide, and now NASH prevalence is estimated to be 2.3% of the general population in India. Owing to the current lifestyle, NASH will be more prevalent and become a serious medical issue, but still no impactful therapeutics exists. Oriental medicine could promise new therapeutics for NASH or NAFLD in the future, and this study provides us useful information using a classical case of NASH.

Acknowledgements

This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 20100028119)

Reference


